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Background: hiPSCs are generated through epigenetic reprogramming of somatic tissue. Genomic imprinting is an
epigenetic phenomenon through which monoallelic gene expression is regulated in a parent-of-origin-specific
manner. Reprogramming relies on the successful erasure of marks of differentiation while maintaining those
required for genomic imprinting. Loss of imprinting (LOI), which occurs in many types of malignant tumors, would
hinder the clinical application of hiPSCs.
Results: We examined the imprinting status, expression levels and DNA methylation status of eight imprinted
genes in five independently generated hiPSCs. We found a low frequency of LOI in some lines. Where LOI was
identified in an early passage cell line, we found that this was maintained through subsequent passages of the
cells. Just as normal imprints are maintained in long-term culture, this work suggests that abnormal imprints are
also stable in culture.
Conclusions: Analysis of genomic imprints in hiPSCs is a necessary safety step in regenerative medicine, with
relevance both to the differentiation potential of these stem cells and also their potential tumorigenic properties.
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pluripotent cellsBackground
Human induced pluripotent stem cells (hiPSCs) represent a
promising therapeutic tool for many diseases, and might be
useful for regenerating aged tissues and organs at high risk
of failure [1,2]. However, the intrinsic self-renewal and
pluripotency of hiPSCs potentially make them tumorigenic,
hindering their clinical application [3-5]. hiPSCs are gener-
ated through epigenetic reprogramming of somatic tissue.
It was initially thought that hiPSCs and human embryonic
stem cells (hESCs) shared a high degree of epigenetic
similarity [6,7]. However, recent reports have indicated
that substantial differences exist between hiPSCs and
hESCs with regard to gene expression, miRNA expression* Correspondence: umezawa@1985.jukuin.keio.ac.jp; tarima@med.tohoku.ac.jp
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reproduction in any medium, provided the orand DNA methylation [8-10]. Cell-of–origin-specific gen-
etic and epigenetic differences exist in hiPSCs [11] and
some of these stem cell lines spontaneously differentiate
during serial passage [12]. Extensive evaluation of
hiPSCs is consequently an essential component of the
process required for their safe use in regenerative
medicine.
Many types of malignant tumors are characterized by
complex genetic and epigenetic alterations, including loss
of heterozygosity (LOH) and loss of imprinting (LOI)
[13,14]. Such alterations are presumed to represent the sec-
ond hit, according to Knudson’s two-hit hypothesis (OMIM
#167000) [15]. However, alterations in DNA methylation
can also occur as the first hit during human carcinogenesis
[16]. Alterations in the expression of imprinted genes
represent one of the most common changes seen in cancer
[17,18]. Some imprinted genes, including H19 [19], GTL2
[20], PEG1, PEG3 [21], LIT1 (KCNQ1OT1) [22] and ZAC
[23] are known to act, or are strongly implicated to act, astd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 LOI and MOI in hiPSCs
H19 IGF2 PEG3 PEG1 GTL2 KCNQ1 NDN LIT1
(RsaI) (ApaI) (MnlI) (AflIII) (TaaI) (SmaI) (MboI) (RsaI)
Cell Passage gDNA cDNA gDNA cDNA gDNA cDNA gDNA cDNA gDNA cDNA gDNA cDNA gDNA cDNA gDNA cDNA
AM936EP P9 a/b a b - a - b - a/b a a - b - a/b a
AM-iPS -2 P13 a/b a b - a - b - a/b a a - b - a/b a
AM-iPS -2 P19 a/b a b - a - b - a/b a a - b - a/b a
AM-iPS -2 P35 a/b a b - a - b - a/b a a - b - a/b a
AM-iPS -3 P9 a/b a b - a - b - a/b a a - b - a/b a
AM-iPS -3 P21 a/b a b - a - b - a/b a a - b - a/b a
AM-iPS -3 P29 a/b b b - a - b - a/b a a - b - a/b a
AM-iPS -3 P36 a/b a b - a - b - a/b a a - b - a/b a
AM-iPS -7 P12 a/b a b - a - b - a/b a/b a - b - a/b a
AM-iPS -7 P22 a/b a b - a - b - a/b a/b a - b - a/b a
AM-iPS -7 P32 a/b a b - a - b - a/b a/b a - b - a/b a
AM-iPS -8 P13 a/b a b - a - b - a/b a a - b - a/b a
AM-iPS -8 P20 a/b a b - a - b - a/b a a - b - a/b a
AM-iPS -8 P37 a/b a b - a - b - a/b a a - b - a/b a
AM-iPS -20 P8 N.T. a N.T. - N.T. - N.T. - N.T. a N.T. - N.T. - N.T. a
AM-iPS -20 P11 a/b a b - a - b - a/b a a - b - a/b a
AM-iPS -20 P14 a/b a b - a - b - a/b a a - b - a/b a
AM-iPS -20 P16 a/b N.D. b - a - b - a/b a a - b - a/b a
AM-iPS -20 P32 a/b N.D. b - a - b - a/b a a - b - a/b a
PL551Ar P16 a/b a a/b a b - a/b N.D. b - b N.D. a - a -
PAE-iPS -05 P19 a/b a a/b N.D. b - a/b N.D. b - b - a - a -
PAE-iPS -05 P31 a/b a a/b N.D. b - a/b N.D. b - b - a - a -
PAE-iPS -11 P14 a/b a a/b N.D. b - a/b N.D. b - b - a - a -
PAE-iPS -11 P18 a/b a a/b N.D. b - a/b N.D. b - b - a - a -
PAE-iPS -11 P30 a/b a a/b N.D. b - a/b N.D. b - b - a - a -
MRC-5 - a/b N.D. b - a - b - a/b a/b a/b N.D. a/b N.D. a -
MRC-iPS -16 P30 a/b N.D. b - a - b - a/b ND a/b b a/b a a -
MRC-iPS -25 P6 a/b N.D. b - a - b - a/b ND a/b b a/b a a -
MRC-iPS -25 P30 a/b N.D. b - a - b - a/b ND a/b b a/b a a -
MRC-iPS -40 P11 a/b N.D. b - a - b - a/b ND a/b b a/b a a -
MRC-iPS -40 P30 a/b N.D. b - a - b - a/b ND a/b b a/b a a -
UtE1104 P9 a/b N.D. a - a/b a/b a/b b a/b a/b b N.D. b - a -
UtE-iPS -6 P20 a/b N.D. a - a/b a/b a/b a/b a/b a/b b - b - a -
UtE-iPS -6 P31 a/b b a - a/b a/b a/b a/b a/b a/b b - b - a -
UtE-iPS -11 P13 a/b N.D. a - a/b N.D. a/b a/b a/b a b N.D. b - a -
UtE-iPS -11 P20 a/b N.D. a - a/b N.D. a/b a/b a/b a/b b N.D. b - a -
UtE-iPS -11 P30 a/b N.D. a - a/b N.D. a/b a/b a/b a b - b - a -
Edom22 P5 b - a/b a/b a - a/b b b - a/b a a - a -
Edom-iPS -1 P27 b - a/b N.D. a - a/b b b - a/b a a - a -
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Table 1 LOI and MOI in hiPSCs (Continued)
hES 3 P29 a/b a b - a/b a a/b b b - a - a/b b a -
SEES 1 P10 a/b a a/b a a - b - a/b b a - a - a -
SEES 4 P9 a/b b a/b a a - b - b - a - a/b b a -
A summary of LOI and MOI RFLP data for the 8 imprinted genes analyzed in 22 hiPSCs and 3 control hES cell lines. hiPSCs derived from extraembryonic amniotic
membrane (AM-iPS), embryonic lung tissue (MRC-iPS), uterine endometrium (UtE-iPS), adult menstrual blood (Edom-iPS) and extraembryonic placental tissue (PAE-
iPS). Samples were analyzed at the specified passage number. (-): not informative.
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http://www.biomedcentral.com/1471-2156/14/32tumor suppressor genes (TSGs). Furthermore, imprinted
genes play key roles in regulating growth and differenti-
ation [24]. Thus the aberrant expression of imprinted
genes may contribute to tumorigenesis or alter the
differentiation potential of stem cells.
The monoallelic expression of imprinted genes is reliant
on epigenetic mechanisms, most notably DNA methylation,
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Figure 1 Loss of imprinting in hiPSCs. Loss of allelic expression of GTL2
products amplified from paired genomic DNA and cDNA samples were dig
confirmed by direct sequencing (B). AM936EP and UtE1104 are primary cu
cells, respectively. Band ‘a’: without a restriction site. Band ‘b’: with a restrictdiscrete locations termed germline or gametic differentially
methylated regions (gDMRs) [25]. Imprinted domains
generally contain several genes displaying allele-specific
expression and gDMRs within these domains act as
imprinting centers or imprint control regions for the
domain [26]. The majority of imprinted genes reside
within these complex domains [27]. Although gametic
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in cell line AM-iPS-7 (1) and PEG1 in cell lines UtE-iPS-6 and 11 (2). PCR
ested with the specified restriction enzymes (A). Results were
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Figure 2 Reduced expression of hiPSCs with LOI. Gene expression levels of GTL2 (A) and PEG1 (B) in the original and the passaged hiPSCs
were compared to that of hESCs. The GAPDH ratio was calculated. The bars indicate the means ± standard deviation (SD) from two replicates.
N.D.: not determined.
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developmentally specific manners [28].
In a recent paper, we demonstrated that hiPSCs ex-
hibit epigenetic patterns distinct from hESCs [29]. After
continuous passaging of the hiPSCs, these differences
diminished such that over time the hiPSCs more closely
resembled hESCs. However, we found that the imprinted
DMRs showing abnormal methylation in early passage
hiPSCs did not resolve during passaging. In this study
we focused on the expression of imprinted genes in
hiPSCs. Several reports on imprinted gene expression in
hESCs demonstrate a substantial degree of instability
[30]. Less is known regarding the stability of imprints in
hiPSCs, although some work has begun [31]. We are
particularly concerned with the stability of imprints in
pluripotent stem cells during prolonged culture. Here,
we examined the imprinting status and expression levels
of eight imprinted genes and the methylation status of
their DMRs in five independently derived hiPSCs. We
found that the frequency LOI was very low in the early
passaged lines. We also found that, in contrast, the
epigenetic changes that took place at non-imprinted
loci during prolonged culture for both normal and aberrantimprints were stably inherited despite prolonged passaging
of the lines.
Results
Loss of heterozygosity (LOH) and loss of imprinting (LOI)
in hiPSCs
We first determined whether hiPSCs showed LOH by
comparing the restriction fragment length polymorphism
(RFLP) patterns of the original tissue DNA with those of the
hiPSC DNA samples. Samples in which RFLPs were present
in the original DNA sample but absent or with an altered
ratio in the hiPSC samples were considered to exhibit LOH.
We found no evidence for LOH at the 8 loci tested
(H19, IGF2, KCNQ1, LIT1, GTL2, PEG1, PEG3 and NDN).
We next performed RT-PCR and RFLP analyses to iden-
tify samples that demonstrated loss of imprinting (LOI).
Where expression of genes was low in undifferentiated
cells, it was not possible to determine their imprinting
status (H19 in MRC-iPS and UtE-iPS, IGF2 in PAE-iPS and
GTL2 in Edom-iPS). Of the 16 informative loci, we identi-
fied LOI at three loci in hiPSCs, GTL2, PEG1 and PEG3,
but we did not detect any LOI in hESCs (Table 1). Of par-

































































































































































































































































































































































































































































































































































































Figure 3 (See legend on next page.)
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Figure 3 Aberrant DNA methylation of hiPSCs with LOI. Bisulfite PCR sequencing methylation assay of genomic DNA prepared from AM-iPS-7
and MRC-iPS-25 at the IG-DMR (GTL2-DMR) (A) and UtE-iPS-6 and 11 at PEG1 (B). Each row represents a unique methylation profile within the
pool of 20 clones sequenced. Closed and open circles represent methylated and unmethylated CpGs, respectively. The numbers represent the
percentages of methylation by bisulfite sequencing. SNPs are shown by arrows.
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(PEG1) lines (Figure 1A). Where LOI was observed in early
passage cells, this was maintained even after 30 or more
passages (Figure 1).Expression level of the imprinted genes in hiPSCs
LOI can refer to silencing of an originally active allele or
expression of a normally silent allele. Therefore, we com-
pared the expression levels of the three genes that displayed
LOI in hiPSCs and hESCs (Table 1). The expression of
IGF2 and GTL2 was decreased in almost all the hiPSC lines
in comparison with the hES cells (Additional files 1 and 2).
GTL2 in cell line AM-iPS-7 and PEG1 in line UtE-iPS-11
showed apparent biallelic expression but their expression
levels were relatively low in comparison to hESCs with
reduced expression maintained stably through to late
passages (Figure 2). In contrast, expression of PEG1 in cell
line UtE-iPS-6 was not significantly different from that of
hESCs. These results were in accordance with the DNA
microarray analysis data we already reported [29]. Since, in
two cases, LOI correlated with reduced gene expression, this
has potential functional implications due to loss of function.Analysis of the DNA methylation status and the histone
modification of GTL2 and PEG1 DMRs in hiPSC lines
We determined the allele-specific methylation status of the
GTL2 (IG-DMR) and PEG1 imprinted DMRs using poly-
morphic bisulfite-PCR sequencing (Figure 3). In cell line
AM-iPS-7, which showed LOI and reduced expression of
GTL2, we observed hypermethylation of IG-DMR, which
was maintained during continuous passaging. IG-DMR
methylation is normally present on the silent allele of GTL2
[32], which suggests aberrant signaling between this DMR
and GTL2 expression. In cell line UtE-iPS-11, in which
there was LOI and reduced expression of PEG1, abnormal
methylation was detected in passage 31 cells but not earlier
passages. In cell line UtE-iPS-6, in which there was LOI but
not reduced expression of PEG1, abnormal methylation
was not detected. Allele-specific expression of some genes
has been reported to be regulated by histone modification
rather than direct DNA methylation [33-35]. We therefore
analyzed histone modifications in the hiPS cell line by chro-
matin immunoprecipitation (ChIP) analyses using the
following antibodies: dimethylated H3-Lys4 (H3K4me2),
acetylated H3-Lys9 (H3K9ac), H3K9me2, and H3K27me3.
H3K4me2 and H3K9ac mark active genes and H3K9me2
and H3K27me3 are repressive marks. In the GTL2promoter region, H3K9me2 and H3K27me3 were enriched
in AM-iPS-7 and MRC-iPS-25 cells (Figure 4D).
Reactivation of the imprinted genes by the HDACi treatment
Previous reports demonstrated that the GTL2 gene was
aberrantly silenced in most mouse iPSC lines but that
expression could be restored through HDACi treatment
[36,37]. In our study, AM-iPS and MRC-iPS cells showed
LOI of GTL2, with a reduction in gene expression and
hypermethylation of the IG-DMR. To assess whether
GTL2 expression could be restored, AM-iPS and MRC-
iPS cells were treated with the HDAC inhibitor VPA
(sodium valproate). VPA-treated cells did achieve a
3.0–5.8-fold increase in GTL2 expression levels (Figure 4A)
and H3K4me2 and H3K9ac were enriched in its promoter
region (Figure 4D). However, the DNA methylation pattern
was stable under VPA treatment and the imprinting
status of GTL2 was not changed, with cells maintaining
biallelic expression of the gene (Figure 4B). These
results suggested that the aberrant DNA methylation
and imprinting that were established and maintained
in early passages (Figure 4C) were not sustainably reversed
by the treatment.
Discussion
Most hES and hiPS cell lines possess stable imprinted
gene expression, at least in undifferentiated cells [30,31
and findings in this study]. This implies that imprints
withstand the process of reprogramming and the rigors
of growing in culture. In our study, we found that only
three of the 22 hiPS cell lines we derived from a variety
of somatic cell types showed LOI, and at only a few sites.
The majority of cases had normal imprinting status.
While LOI was rare in our hiPS cell lines, we found that
it was maintained during prolonged passage, and resistant
to VPA treatment. These abnormalities would preclude
the use of these cell lines for therapeutic applications but
might provide a mechanistic insight relevant to imprinting
and reprogramming.
We previously reported that abnormal DNA methylation
detected in early passage iPSCs diminished after continued
passaging, such that these cells ultimately more resembled
ESCs. However, abnormal DNA methylation at imprinted
loci in ESCs occurs in response to continuous passaging
[29]. Rugg-Gunn et al. suggested three possible explana-
tions for LOI in hESCs [30]. First, the developmental onset
of transcription might influence imprinted gene expression.

















































































































































































































































































































Figure 4 (See legend on next page.)
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Figure 4 Reactivation of GTL2 expression by treatment with VPA. Reactivation of GTL2 expression by treatment with VPA (A). The expression
level of GTL2 mRNA was restored by VPA treatment. Gene expression of the original cells and of the hiPSCs was compared to that of hESCs. The
GAPDH ratio was calculated. The bars indicate the means ± SD from two replicates. The imprinting status of GTL2 was stable in response to VPA
(B). Methylation status in bisulfite-PCR sequencing analyses of IG-DMR is unchanged (C). Histone modifications of the GTL2 promoter were
changed by VPA (D). The immunoprecipitation/input ratio was calculated. The bars indicate the means ± SD from three replicates.
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paternally inherited methylation. Third, the pattern of
imprinted gene expression might depend on whether the
gene provides a growth advantage to hESCs. These possibil-
ities might also apply to hiPSCs.
There are two caveats that apply to this work. First,
we examined expression in undifferentiated cells. Con-
sequently, we may have missed changes in imprinted
gene expression where genes are expressed only in dif-
ferentiated cells or where imprinting is tissue specific.
Second, we examined total levels of expression and total
methylation patterns of populations of cells. Therefore
we cannot exclude the possibility that a small population
within our samples could behave in a different manner
from the general population. Nonetheless, our data are
encouraging in suggesting that imprinting errors in iPSCs
are derived from a variety of human somatic cell types.
One of the key advantages of iPSCs is that they can be
derived from patients, supporting the further investigation
of certain diseases, as well as the replacement of
degenerated and damaged tissues. Careful analysis of
imprinted genes should therefore be performed on all
iPS cell lines since several published iPS cell lines that
passed the necessary reprogramming criteria also showed
aberrations in imprinted gene expression and DNA methy-
lation of DMRs. This is particularly critical if these hiPSs
are to be used for regenerative medicine since aberrations
in imprinted genes could cause problems with cell differen-
tiation and perhaps even cause tumors [38]. The analysis of
imprinted genes is also essential for modeling of genetic
diseases because abnormal imprinting can seriously confuse
the disease phenotyping.
Recent advances in high-throughput technologies for
gene expression analysis and DNA methylation analysis
indicate the possibility that all newly generated stem cell
lines can be characterized at the epigenetic level rapidly
and precisely. However, our work and that of others suggest
that certain imprinted loci may be more susceptible to
LOI. This means that it might be possible to design
targeted assays for specific loci as the first step in the
characterization of newly generated cell lines, and also
those that have been extensively passaged.
Conclusions
In conclusion, while imprinting errors may be rare in
iPSCs, they are resistant to reversal strategies. The aberrant
expression of imprinted genes in these lines is likely tohamper their use both for the understanding of certain
pathologies and regenerative medicine.
Methods
Ethics statement
All experiments handling human cells and tissues were
performed in line with the tenets of the Declaration of
Helsinki. This study was approved by the Institutional
Review Board of the National Institute for Child Health
and Development and the Ethics Committee of Tohoku
University School of Medicine.
DNA/RNA preparation of iPSCs
We generated 22 hiPSCs from extraembryonic amniotic
membrane (AM-iPS), embryonic lung tissue (MRC-iPS),
uterine endometrium (UtE-iPS), adult menstrual blood
(Edom-iPS), and extraembryonic placental tissue (PAE-iPS)
and characterized the pluripotent nature using culture
methods described previously [39-41]. Prior to RNA and
DNA preparation, feeder layers were removed from the
undifferentiated cells by panning for 20 minutes.
Loss of heterozygosity (LOH) and loss of imprinting (LOI)
analyses
PCR was performed on parental tissue and the genomic
DNA of hiPSCs using the primer sequences summarized
in Additional file 3. A PCR reaction mix containing 0.5
μM concentrations of each primer set, 200 μM dNTPs,
1× PCR buffer, and 1.25U of EX Taq Hot Start DNA
Polymerase (Takara Bio, Tokyo, Japan) in a total volume
of 20 μl was used. The following PCR program was used:
1 minute of denaturation at 94°C followed by 35 cycles
of 30 seconds at 94°C, 30 seconds at 50-70°C, 30 seconds at
72°C and a final extension for 5 minutes at 72°C. PCR
products were digested by unique polymorphic enzymes to
identify samples that were heterozygous for a single
nucleotide polymorphism (SNP). For samples found to
be heterozygous for a SNP, RNA was prepared from
matched hiPSCs, followed by reverse transcription-PCR
(RT-PCR) and restriction digestion (Additional file 3)
[42-49]. The digested PCR products were electrophoresed
on 3% agarose gel.
Gene expression analysis
RNA expression levels of 8 imprinted genes were also ana-
lyzed by microarray and the real-time PCR. Microarray
analysis was performed using an Agilent Whole Human
Hiura et al. BMC Genetics 2013, 14:32 Page 9 of 11
http://www.biomedcentral.com/1471-2156/14/32Genome Microarray chip (G4112F, Agilent, Santa Clara,
CA). Raw data were normalized and analyzed using
GeneSpringGX11 software (Silicon Genetics, Redwood
City, CA). The microarray data have been deposited in
Gene Expression Omnibus (http://www.ncbi.nlm.nih.
gov/geo/). Real-time PCR reaction was done with SYBR
Premix Ex Taq II (Takara Bio). In the case of PEG3 ex-
pression analysis, TaqMan Gene Expression Assay
(Assay ID: Hs00300418-s1, Applied Biosystems, Foster
City, CA) was carried out according to the manufacturer’s
protocol using a StepOne Real-time PCR System (Applied
Biosystems). The relative expression levels of the detected
genes from these cells were estimated visually by compar-
ing relative band intensities with the expression level of
the housekeeping gene GAPDH.
Polymorphic bisulfite PCR methylation assay
We performed standard methylation assays using the
SNPs and bisulfite sequencing [50]. The primary DMRs
of eight imprinted genes (H19, GTL2, ZDBF2, PEG1,
KCNQ1OT1, ZAC, PEG3 and SNRPN) were analyzed as
described previously [50,51]. Each DNA sample was
treated with sodium bisulfite using the EZ methylation
kit (Zymo Research, Orange, CA) and amplified by PCR.
PCR products were purified, cloned into pGEM-T
(Promega, Medison, WI) and an average of 20 clones
per individual were sequenced using reverse primer
M13 and an automated ABI Prism 3130xl Genetic
Analyzer (Applied Biosystems). To avoid any allelic bias,
we used specific polymorphic sites. Sodium bisulfite
modification treatments were carried out in duplicate
for each DNA sample and at least three independent
amplification experiments were performed for each in-
dividual examined.
Chromatin immunoprecipitation (ChIP) assay
ChIP analysis was performed using the Magna ChIP
G Chromatin Immunoprecipitation Kit (Millipore,
Temecula, CA) according to the manufacturer’s protocol.
We used the following antibodies: dimethylated H3-
Lys4, acetylated H3-Lys9, dimethylated H3-Lys9 and
trimethylated H3-Lys27 (Millipore). The histone modi-
fications were analyzed by real-time PCR. Real-time
PCR reaction was done with SYBR Premix Ex Taq II
(Takara Bio). The amount of precipitated DNA was
determined as percentage relative to input DNA. Primers
used are listed in Additional file 3.
Treatment of cells with sodium valproate
hiPSCs were plated at a density of 5 × 105 cells/60mm2
dish. Twenty-four hours later, they were treated with 1
mM sodium valproate (Wako, Tokyo, Japan) for the
times stated. Total RNA was prepared and analyzed by
the RT-PCR method. The methylation status of theDMRs was examined using the bisulfite PCR sequencing
methylation assay described previously [51].
Additional files
Additional file 1: Microarray analysis. Scatter plots of MRC-iPS-25P22
versus hES3 (A) and UtE-iPS-6P30 versus hES3 (B). Scatter plot comparing
the spot intensities in hybridization with probes from hiPSCs (y axis) and
hESCs (x axis). The magenta plots indicate the imprinted genes.
Additional file 2: Gene expression analysis of the imprinted genes.
H19 (A), IGF2 (B), PEG3 (C), PEG1 (D), GTL2 (E), KCNQ1 (F), NDN (G) and
LIT1 (H). Gene expression of the original and hiPSCs was compared to
that of hESCs. The GAPDH ratio was calculated. The bars indicate the
means ± SD from two replicates.
Additional file 3: PCR primers and conditions.
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